Top

Nicholas James Short, MD

Department of Leukemia, Division of Cancer Medicine

About Dr. Short

Dr. Nicholas Short is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He attended Baylor College of Medicine for medical school, and then completed internal medicine residency at Brigham and Women’s Hospital, followed by hematology/oncology fellowship at The University of Texas MD Anderson Cancer Center.

Dr. Nicholas Short is a clinical and translational investigator in adult acute leukemias, with a particular emphasis on the prognostic and therapeutic impact of measurable residual disease (MRD) and the development of phase I and II clinical trials of novel agents and combinations for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). He serves as principal investigator or co-principal investigator on over a dozen phase I and II clinical trials and has authored over 200 peer-reviewed manuscripts and numerous abstracts that have been presented at national and international conferences, including the American Society of Hematology and the American Society of Clinical Oncology.

For his accomplishments in the field of leukemia research he has received a number of awards, including the American Society of Clinical Oncology Young Investigator Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research.

Meet Nicholas Short, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2022	The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, US, M.S. in Biomedical Sciences
2011	Baylor College of Medicine, Houston, Texas, US, MD
2006	Rice University, Houston, Texas, US, BA in Philosophy

Postgraduate Training

2014-2017	Clinical Fellowship, Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2011-2014	Clinical Residency, Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts

Board Certifications

2017	Hematology, American Board of Internal Medicine
2017	Medical Oncology, American Board of Internal Medicine
2014	Internal Medicine, American Board of Internal Medicine

Experience & Service

Academic Appointments

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

Institutional Committee Activities

Core Development Lead, ALL and AML Algorithm, 2022 - Present

Reviewer, Institutional Research Grant Committee, 2020 - Present

Member, Department of Biostatistics New Faculty Selection Committee, 2019 - Present

Member, Clinical Research Committee (CRC) #2, 2018 - Present

Faculty Judge, Trainee Research Day, 2018 - 2019

Faculty Lecturer, Comprehensive Board Review in Hematology and Medical Oncology, 2018 - 2020

Core Development Team Leader, Tumor Lysis Syndrome Working Group, 2017 - Present

Honors & Awards

2019	Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of Hematology
2019	Junior Faculty Scholar Award in Clinical Research, American Society of Hematology
2018	Paul Calabresi Clinical Oncology Scholar, K12 Award
2017	Career Enhancement Award, Leukemia SPORE
2017	Merit Award, American Society of Clinical Oncology
2017	Next Gen Innovator, HemOnc Today
2017	Shannon Timmins Fellowship for Leukemia Research, The University of Texas MD Anderson Cancer Center
2017	Young Investigator Award, American Society of Clinical Oncology
2016	Future Leaders in Hematology Award, Celgene
2016	Kimberly Patterson Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center
2016	Young Investigator Award, American Journal of Hematology
2015	Abstract Achievement Award, American Society of Hematology
2014	Certificate for Excellence in Tutoring, Harvard Medical School
2011	Harry and Rose Caplovitz Internal Medicine Award, Baylor College of Medicine
2011	Stanley W. Olson Award for Academic Excellence and Service, Baylor College of Medicine
2010	Member, Alpha Omega Alpha Honor Society
2010	Michael E. DeBakey Scholar, Baylor College of Medicine
2009	Highest Honor for Pre-Clinical Academic Performance, Baylor College of Medicine
2007	Member, Phi Beta Kappa Honor Society
2007	Outstanding Premedical Student, John P. McGovern
2003	Medical Scholar, Rice University/Baylor College of Medicine
2003	Trustee Distinguished Scholar, Rice University
2003	Century Scholar, Rice University

Professional Memberships

Harris County Medical Society

2018 - Present

Texas Medical Association

2018 - Present

European Hematology Association

2017 - Present

Society of Hematologic Oncology

2015 - Present

American Society of Clinical Oncology

2014 - Present

American Society of Hematology

2014 - Present

Selected Publications

Peer-Reviewed Articles

Jen WY, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, Loghavi S, Daver NG, DiNardo CD, Issa GC, Abbas HA, Nasnas C, Bataller A, Urrutia S, Karrar OS, Pierce SA, Kantarjian HM, Short NJ. Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy. Blood Adv, 2024. e-Pub 2024. PMID: 39631072.
Haddad, FG, Sasaki, K, Senapati, J, Xiao, L, Park, GS, Abuasab, T, Venugopal, S, Rivera, D, Bazinet, A, Babakhanlou, R, Kim, K, Ong, F, Desikan, SP, Pemmaraju, N, Loghavi, S, Borthakur, G, DiNardo, C, Abbas, HA, Short, NJ, Daver, N, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis. JCO Oncology Practice 20(12):1637-1644, 2024. e-Pub 2024. PMID: 39013130.
Short NJ, Wierzbowska A, Cluzeau T, Laribi K, Recher C, Czyz J, Ochrem B, Ades L, Gallego-Hernanz MP, Heiblig M, Audisio E, Zarzycka E, Li S, Ferenc N, Yeh T, Faller DV, Sedarati F, Papayannidis C. Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma:1-11, 2024. e-Pub 2024. PMID: 39606906.
Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer, 2024. e-Pub 2024. PMID: 39584789.
Urrutia S, Kantarjian HM, Ravandi-Kashani F, Bueso-Ramos C, Kanagal-Shamanna R, Jabbour E, Montalban-Bravo G, Short NJ, Daver N, Borthakur G, Dinardo CD, Kadia TM, Masarova L, Bose P, Pemmaraju N, Garcia-Manero G, Sasaki K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol 17(1):112, 2024. e-Pub 2024. PMID: 39548557.
McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, Kadia, TM. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594839.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
Jen WY, Jabbour E, Short NJ, Issa GC, Haddad FG, Jain N, Pemmaraju N, Daver NG, Masarova L, Borthakur G, Chien K, Garris R, Kantarjian HM. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol 99(11):2229-2232, 2024. e-Pub 2024. PMID: 39194286.
Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
Haddad, FG, Sasaki, K, Nasr, L, Short, NJ, Kadia, TM, Dellasala, S, Cortes, JE, Nicolini, F, Issa, GC, Jabbour, EJ, Kantarjian, HM. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130(19):3344-3352, 2024. e-Pub 2024. PMID: 38804723.
Haddad, FG, Sasaki, K, Nasr, L, Short, NJ, Kadia, TM, Dellasala, S, Cortes, JE, Nicolini, F, Issa, GC, Jabbour, EJ, Kantarjian, HM. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130(19):3344-3352, 2024. e-Pub 2024. PMID: 38804723.
Ali, MA, Aiman, W, Kantarjian, HM, Jabbour, EJ, Ravandi-Kashani, F, Jain, N, Short, NJ, Sasaki, K. Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(10):e376-e384, 2024. e-Pub 2024. PMID: 38972767.
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma 65(10):1511-1515, 2024. e-Pub 2024. PMID: 38856690.
Gibson A, Nunez C, Robusto L, Kammerer B, Garcia M, Roth M, Sheth R, Tewari P, Hittle A, Toepfer L, Torres R, Short NJ, Jabbour E, Jain N, Cuglievan B, McCall D. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica 109(9):3042-3047, 2024. e-Pub 2024. PMID: 38779719.
Jabbour, EJ, Haddad, FG, Sasaki, K, Carter, BZ, Alvarado, Y, Nasnas, C, Nasr, L, Masarova, L, Daver, N, Pemmaraju, N, Short, NJ, Skinner, J, Kadia, TM, Borthakur, G, Garcia-Manero, G, Ravandi-Kashani, F, Issa, GC, Andreeff, M, Kantarjian, HM. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
Akiyama, H, Kantarjian, HM, Jabbour, EJ, Issa, GC, Haddad, FG, Short, NJ, Hu, S, Ishizawa, J, Andreeff, M, Sasaki, K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol:JCO2400272, 2024. e-Pub 2024. PMID: 39028925.
Abuasab, T, Borthakur, G, Kanagal Shamanna, R, Masarova, L, Patel, KP, Takahashi, K, Bose, P, Villarreal, J, Pierce, S, Kadia, TM, Garcia-Manero, G, Short, NJ, DiNardo, C, Daver, N, Ravandi-Kashani, F, Kantarjian, H, Verstovsek, S, Yilmaz, M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms. American journal of hematology 99(7):1434-1436, 2024. e-Pub 2024. PMID: 38613831.
Montalban Bravo, G, Jabbour, EJ, Chien, KS, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Daver, N, Kanagal-Shammana, R, Loghavi, S, Qiao, W, Huang, X, Schneider, H, Meyer, M, Kantarjian, HM, Garcia-Manero, G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142, 2024. e-Pub 2024. PMID: 38744144.
Short, NJ, Jabbour, EJ, Nasr, L, Jain, N, Haddad, FG, Issa, GC, Sasaki, K, Senapati, J, Kebriaei, P, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. American journal of hematology 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
Jen, WY, Sasaki, K, Loghavi, S, Wang, S, Qiao, W, Borthakur, G, Ravandi-Kashani, F, Kadia, TM, Issa, GC, Short, NJ, Yilmaz, M, Daver, N, DiNardo, C. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. British Journal of Haematology 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
Khouri, IF, Alzahrani, K, Kantarjian, HM, Milton, D, Gulbis, A, Sasaki, K, Jain, N, Short, NJ, Kadia, TM, Daher, M, Rafei, H, Im, JS, Marin, D, Olson, AL, Popat, UR, Qazilbash, MH, Ramdial, JL, Rondon, G, Srour, S, Kebriaei, P, Shpall, E, Champlin, RE, Jabbour, EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. American journal of hematology 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
Kang, DW, Wang, L, Short, NJ, Ferrajoli, A, Wang, Y, Zhou, S, Shen, C. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. PharmacoEconomics 42(4):409-418, 2024. e-Pub 2024. PMID: 38184494.
Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Bataller, A, DiNardo, C, Bazinet, A, Daver, N, Maiti, A, Borthakur, G, Short, NJ, Sasaki, K, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. American journal of hematology 99(4):792-796, 2024. e-Pub 2024. PMID: 38361282.
Short, NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(4):e168-e173, 2024. e-Pub 2024. PMID: 38212207.
Modak RV, de Oliveira Rebola KG, McClatchy J, Mohammadhosseini M, Damnernsawad A, Kurtz SE, Eide CA, Wu G, Laderas T, Nechiporuk T, Gritsenko MA, Hansen JR, Hutchinson C, Gosline SJC, Piehowski P, Bottomly D, Short N, Rodland K, McWeeney SK, Tyner JW, Agarwal A. Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia. Clin Cancer Res. e-Pub 2024. PMID: 38451486.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
Zhao Y, Short, NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. e-Pub 2024. PMID: 38551807.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. e-Pub 2024. PMID: 38418609.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38431521.
Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38403505.
Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
Short, NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica 109(1):293-297, 2024. e-Pub 2024. PMID: 37646654.
Short, NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol:JCO2301911. e-Pub 2024. PMID: 38277619.
Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37735426.
Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer 129(23):3805-3814, 2023. e-Pub 2023. PMID: 37769040.
Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv 7(21):6492-6505, 2023. e-Pub 2023. PMID: 37647601.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98(10):E281-E284, 2023. e-Pub 2023. PMID: 37515433.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
Short, NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol 149(7):3965-3976, 2023. e-Pub 2023. PMID: 36030431.
Short, NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
Short, NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
Desikan SP, Senapati J, Jabbour E, Abuasab T, Short NJ, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. e-Pub 2023. PMID: 37138019.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic Myeloid Leukemia Without Major Molecular Response After 2 Years of Treatment with Tyrosine Kinase Inhibitor. Am J Hematol 98(4):639-644, 2023. e-Pub 2023. PMID: 36606715.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. e-Pub 2023. PMID: 37102976.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046645.
Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2023. PMID: 35405739.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):1-4, 2023. e-Pub 2023. PMID: 36657414.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv. e-Pub 2023. PMID: 36884300.
Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2023. PMID: 36502492.
Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol 98(1):E11-E14, 2023. e-Pub 2023. PMID: 35633516.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
Marx KR, Rausch CR, Lovell AR, Short NJ, Paul S, Jain N, Lee J, Savoy JM, Ravandi F, Jabbour E. Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. Leuk Lymphoma 64(1):1-8, 2023. e-Pub 2023. PMID: 36222579.
Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Gonzalez GN, Hwang H, Qi X, Kantarjian H, Zhou S, Ravandi F. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia 36(12):2817-2826, 2022. e-Pub 2022. PMID: 36261575.
Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. Blood 140(20):2101-2112, 2022. e-Pub 2022. PMID: 35877996.
Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
Haddad, FG, Kantarjian, HM, Short, NJ, Konopleva, M, Jain, N, Huang, X, Ravandi-Kashani, F, Wierda, WG, Borthakur, G, Sasaki, K, Issa, GC, Alvarado, Y, Pemmaraju, N, Garcia-Manero, G, Thankachan, J, Garris, R, Jabbour, EJ. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S204, 2022. e-Pub 2022. PMID: 36163747.
Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. e-Pub 2022. PMID: 36163977.
Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J 12(10):144, 2022. e-Pub 2022. PMID: 36307398.
Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. e-Pub 2022. PMID: 35201293.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol 97(9):1135-1141, 2022. e-Pub 2022. PMID: 35713551.
Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol 8(9):1340-1348, 2022. e-Pub 2022. PMID: 35834222.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. e-Pub 2022. PMID: 35973199.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Liu C, Amin R, Shatila M, Short NJ, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol. e-Pub 2022. PMID: 36030431.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, DiNardo CD, Short NJ, Jain N, Kadia TM, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev 31(6):OF1-OF9, 2022. e-Pub 2022. PMID: 35553621.
Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1448, 2022. e-Pub 2022. PMID: 35411096.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short NJ, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2022. PMID: 34668451.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short NJ, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2022. PMID: 34716921.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008312.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma:1-5. e-Pub 2021. PMID: 34474640.
McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver NG, Kadia TM, DiNardo CD, Yi JS, Cuglievan B. Gilteritinib Combination Therapies in Pediatric Patients with FLT3 Mutated Acute Myeloid Leukemia. Blood Adv. e-Pub 2021. PMID: 34592761.
Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad FG, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia TM, Garcia-Manero G, Garris R, O'Brien SM, Jabbour EJ. Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience. Blood Adv. e-Pub 2021. PMID: 34525185.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. e-Pub 2021. PMID: 34351647.
Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson PA, Jain N, Kantarjian HM, Jabbour EJ. Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. e-Pub 2021. PMID: 34464974.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. e-Pub 2021. PMID: 34343352.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. e-Pub 2021. PMID: 34182597.
Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. e-Pub 2021. PMID: 34138471.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94, 2021. e-Pub 2021. PMID: 34130720.
Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia: A population- based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol 96(6):650-658, 2021. e-Pub 2021. PMID: 33709456.
Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. e-Pub 2021. PMID: 34161631.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol 96(5):589-598, 2021. e-Pub 2021. PMID: 33639000.
Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. e-Pub 2021. PMID: 33990705.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol:JCO2003736. e-Pub 2021. PMID: 34043428.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. e-Pub 2021. PMID: 33991360.
Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. e-Pub 2021. PMID: 33818756.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. e-Pub 2021. PMID: 33793970.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. e-Pub 2021. PMID: 33846541.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. e-Pub 2021. PMID: 33793964.
Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. e-Pub 2021. PMID: 33891709.
Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. e-Pub 2021. PMID: 33823073.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica Online ahead of print(4):0, 2021. e-Pub 2021. PMID: 33297667.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. e-Pub 2021. PMID: 33780038.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. e-Pub 2021. PMID: 33740268.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, Kadia TM, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol:1-8. e-Pub 2020. PMID: 33238261.
Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. e-Pub 2020. PMID: 33030517.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. e-Pub 2020. PMID: 32896301.
Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma:1-5. e-Pub 2020. PMID: 32955970.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8. e-Pub 2020. PMID: 32755333.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32561839.
Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. e-Pub 2020. PMID: 32501545.
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2020. PMID: 32792304.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. e-Pub 2020. PMID: 32457305.
Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol:1-7. e-Pub 2020. PMID: 32289808.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
Ball S, Das A, Vutthikraivit W, Edwards PJ, Hardwicke F, Short NJ, Borthakur G, Maiti A. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Lymphoma Myeloma Leuk 20(2):87-97.e5, 2020. e-Pub 2020. PMID: 31787589.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32099037.
Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol 94(12):1388-1395, 2019. e-Pub 2019. PMID: 31595534.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer 125(13):2233-2241, 2019. e-Pub 2019. PMID: 30861111.
Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated AML. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2019. PMID: 30521114.
Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol 94(2):257-265, 2019. e-Pub 2019. PMID: 30394566.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044-4055, 2018. e-Pub 2018. PMID: 30307611.
Ball S, Vutthikraivit W, Maiti A, Short NJ. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?. Eur J Haematol 101(3):418-420, 2018. e-Pub 2018. PMID: 29791043.
Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2018. PMID: 28616864.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28718728.
Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2018. PMID: 29178361.
Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E. Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in Adults: Current Treatments and Future Perspectives. Clin Adv Hematol Oncol 16(3):216-23, 2018. e-Pub 2018. PMID: 29742077.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol 4(2):230-234, 2018. e-Pub 2018. PMID: 28859185.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk 17(12):897-901, 2017. e-Pub 2017. PMID: 28927784.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma 58(10):2508-2510, 2017. e-Pub 2017. PMID: 28264600.
Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens. Am J Hematol 92(10):E595-E597, 2017. e-Pub 2017. PMID: 28646517.
Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol 92(9):924-928, 2017. e-Pub 2017. PMID: 28556489.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 130(13):1514-1522, 2017. e-Pub 2017. PMID: 28774880.
Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117, 2017. e-Pub 2017. PMID: 28295472.
Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2017. PMID: 27602508.
Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol 91(12):1221-1226, 2016. e-Pub 2016. PMID: 27474808.
Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer 121(21):3869-76, 2015. e-Pub 2015. PMID: 26218678.
Cadge W, Ecklund EH, Short NJ. Constructions of religion and spirituality in the daily boundary work of pediatric physicians. Social Problems 56(4):702-21, 2009. e-Pub 2009.
Cameron IL, Short NJ, Fullerton GD. Characterization of water of hydration fractions in rabbit skeletal muscle with age and time of post-mortem by centrifugal dehydration force and rehydration methods. Cell Biol Int 32(11):1337-43, 2008. e-Pub 2008. PMID: 18723101.
Cameron IL, Short NJ, Fullerton GD. Verification of simple hydration/dehydration methods to characterize multiple water compartments on tendon type 1 collagen. Cell Biol Int 31(6):531-9, 2007. e-Pub 2007. PMID: 17363297.
Cameron IL, Short NJ, Fullerton GD. A simple centrifugal dehydration force method to characterize water compartments in fresh and post-mortem fish muscle. Cell Biol Int 31(5):516-20, 2007. e-Pub 2007. PMID: 17267244.
Cameron IL, Short NJ, Markov MS. Safe alternative cancer therapy using electromagnetc fields. The Environmentalist 27(4):453-6, 2007. e-Pub 2007.
Cameron IL, Sun LZ, Short N, Hardman WE, Williams CD. Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis. Cancer Cell Int 5:23, 2005. e-Pub 2005. PMID: 16045802.
Cameron IL, Short N, Sun L, Hardman WE. Endothelial cell pseudopods and angiogenesis of breast cancer tumors. Cancer Cell Int 5(1):17, 2005. e-Pub 2005. PMID: 15918895.
Hardman WE, Sun L, Short N, Cameron IL. Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogenesis. Cancer Cell Int 5:12, 2005. e-Pub 2005. PMID: 15860128.

Invited Articles

Short NJ, Kantarjian H, Jabbour E. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma 65(10):1405-1417, 2024. e-Pub 2024. PMID: 38850572.
Short NJ, Dillon R. Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development. Am J Hematol, 2024. e-Pub 2024. PMID: 39319951.
Short NJ, Jabbour E, Jain N, Kantarjian H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol 17(1):32, 2024. e-Pub 2024. PMID: 38734670.
Jen WY, Jabbour E, Kantarjian HM, Short, NJ. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38538495.
Short, NJ, Jabbour E, Kantarjian H. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38485650.
Short, NJ, Senapati J, Jabbour E. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Curr Hematol Malig Rep 18(6):234-242, 2023. e-Pub 2023. PMID: 37651057.
Haddad FG, Short, NJ. Treatment discontinuation in chronic myeloid leukemia: When, how, and why?. Am J Hematol 98(11):1670-1672, 2023. e-Pub 2023. PMID: 37753704.
Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J 13(1):142, 2023. e-Pub 2023. PMID: 37696819.
Short, NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol 10(5):e382-e388, 2023. e-Pub 2023. PMID: 37003279.
Haddad FG, Sawyers J, Short, NJ. Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens. Ther Adv Hematol, 2023. e-Pub 2023. PMID: 36755897.
Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37(1):5-17, 2023. e-Pub 2023. PMID: 36309558.
Short NJ, Kantarjian H. Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions. Am J Hematol 97(12):1616-1626, 2022. e-Pub 2022. PMID: 35871436.
Haddad FG, Short NJ. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?. Hematology Am Soc Hematol Educ Program 2022(1):213-217, 2022. e-Pub 2022. PMID: 36485089.
Short, NJ, Jabbour, E. What is the Future of Monoclonal Antibodies in Acute Lymphoblastic Leukemia?. ASCO Dailey News, 2022. e-Pub 2022.
Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leuk Lymphoma 63(8):1-12, 2022. e-Pub 2022. PMID: 35357988.
Paul S, Short NJ. Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management. Curr Oncol Rep 24(4):427-436, 2022. e-Pub 2022. PMID: 35141858.
Short NJ, Kantarjian H, Jabbour E. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22(2):61-66, 2022. e-Pub 2022. PMID: 34561201.
Short NJ, Dombret H, Adès L, Kantarjian H. The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. Cancer J 28(1):29-36, 2022. e-Pub 2022. PMID: 35072371.
Aitken MJL, Ravandi F, Patel KP, Short NJ. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. J Hematol Oncol 14(1):137, 2021. e-Pub 2021. PMID: 34479626.
Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. e-Pub 2021. PMID: 34172894.
Short NJ, Jabbour E. Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S52-S53, 2020. e-Pub 2020. PMID: 32862868.
Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol 13(1):70, 2020. e-Pub 2020. PMID: 32503572.
Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov 10(4):506-525, 2020. e-Pub 2020. PMID: 32014868.
Franquiz MJ, Short NJ. Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy. Biologics 14:23-34, 2020. e-Pub 2020. PMID: 32103893.
Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol 11:2040620720910023, 2020. e-Pub 2020. PMID: 32215194.
Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. Haematologica 104(8):1532-1541, 2019. e-Pub 2019. PMID: 31273094.
Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol 10:2040620719849496, 2019. e-Pub 2019. PMID: 31205644.
Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 10:2040620719827310, 2019. e-Pub 2019. PMID: 30800259.
Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet 392(10147):593-606, 2018. e-Pub 2018. PMID: 30078459.
Short NJ, Kantarjian H, Pui CH, Goldstone A, Jabbour E. SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18(7):439-446, 2018. e-Pub 2018. PMID: 29853276.
Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 13(2):91-99, 2018. e-Pub 2018. PMID: 29423571.
Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. Best Pract Res Clin Haematol 30(3):193-200, 2017. e-Pub 2017. PMID: 29050692.
Short NJ, Jabbour E. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep 19(1):6, 2017. e-Pub 2017. PMID: 28205134.
Short NJ, Ravandi F. Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. Clin Lymphoma Myeloma Leuk 6 Suppl:S25-9, 2016. e-Pub 2016. PMID: 27521321.
Short NJ, Ravandi F. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. Expert Rev Hematol 9(6):529-34, 2016. e-Pub 2016. PMID: 27158854.
Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 19(1):82-93, 2014. e-Pub 2014. PMID: 24319019.

Manuals, Teaching Aids, Other Teaching Publications

Short NJ, Connors JM. Bleeding and Thrombosis in Cancer Patients. Clinical Oncology News: Essential Oncoology, 2017.

Editorials

Short, NJ, Kantarjian, HM, Jabbour, EJ. Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?. Expert review of hematology 17(6):189-191, 2024. PMID: 38726703.
Short NJ, Jabbour E. Counterpoints: Should treatment of chronic myeloid leukemia continue indefinitely?. Clin Adv Hematol Oncol 15(6):489-492, 2017. PMID: 28749909.
Short NJ, Jabbour E. Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive?. Clin Adv Hematol Oncol 14(11):892-894, 2016. PMID: 27930640.

Abstracts

Short N, Kantarjian H, Alvarado Y, Burger J, Jain N, Konopleva M, Ravandi F, DiNardo C, Masarova L, Sasaki K, Thompson P, Ferrajoli A, Jacob J, Milton A, Garris R, Jabbour E. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Desikan S, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, Jabbour E, Daver N, Jain N, Chien K, Maiti A, Montalban-Bravo G, Kadia T, Kwari M, Kantarjian H, Short N. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Short N, DiNardo C, Daver N, Nguyen D, Yilmaz M, Kadia T, Garcia-Manero G, Issa G, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien K, Borthakur G, Delumpa R, Milton A, Pierce S, Jabbour E, Konopleva M, Kantarjian H, Ravandi F. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Venugopal S, Kadia T, Ravandi F, DiNardo C, Daver N, Borthakur G, Konopleva M, Garcia-Manero G, Montalban-Bravo G, Maiti A, Yilmaz M, Issa G, Chien K, Pierce S, Kantarjian H, Short N. Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Short N, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour E, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo C, Daver N, Issa G, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien K, Ravandi F, Kadia T, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce S, Waller L, Banks G, Kantarjian H, Cortex J. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Short N, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia T, Khoury J, Jorgensen J, Wang S, Alvarado Y, Burger J, Daver N, Borthakur G, DiNardo C, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda W, Kornblau S, Jacob J, Kwari M, Rausch C, Loiselle C, Milton A, Rivera J, Garris R, O'Brien S, Jabbour E. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Short N, Kantarjian H, Ravandi F, Huang X, Thompson P, Ferrajoli A, Kadia T, Jain N, Alvarado Y, Yilmaz M, Khoury JD, Jorgensen JL, Wang SA, Kornblau S, Konopleva M, Garcia-Manero G, Garris R, Schroeder H, Milton A, Rivera J, Banks G, Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Short N, Kantarjian H, Konopleva M, Desikan S, Jain N, Ravandi F, Huang X, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, DiNardo C, Thankachan J, Delumpa R, Milton A, Rivera J, Waller L, Garris R, Jabbour E. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
Short N, Kantarjian H, Konopleva MY, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvardo Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Interim Results of a Phase II Study of Blinatumomab Plus Ponatinib for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. EHA, 2021. e-Pub 2021.
Short N, Kantarjian H, Konopleva MY, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvardo Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Combination of Ponatinib and Blinaxtumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study. American Society of Cliical Oncology (ASCO), 2021. e-Pub 2021.
Short, NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz M, Kanagal-Shamanna R, Patel K, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Jabbour E, Yilmaz M, Issa GC, Andreeff M, Kadia T. Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53¬-Mutated Acute Myeloid Leukemia. American Society of Hematology (ASH), 2020. e-Pub 2020.
Short NJ, Kantarjian HM, Ravandi F, Huang X, Ferrajoli A, Kadia TM, Thompson PA, Alvarado Y, Jain N, Yilmaz M, Khoury JD, Jorgensen JL, Wang SA, Kornblau SM, Konopleva M, Garcia-Manero G, Schroeder HM, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien SM, Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. American Society of Hematology (ASH), 2020. e-Pub 2020.
Short NJ, Kantarjian HM, Patel K, Kornblau SM, Jorgensen JL, Wang SA, Konopleva M, Jain N, Kebriaei P, Yilmaz M, Issa GC, Matthews JA, Noor M, Garris R, Ravandi F, Jabbour E. Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. American Society of Hematology (ASH), 2020. e-Pub 2020.
Short NJ, Konopleva M, e J, Kadia T, Daver N, Cook R, Jain N, Ravandi F. Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Hematology (ASH), 2020. e-Pub 2020.
Short NJ, Kantarjian H, Ravandi F, Huang X, Daver N, DiNardo C, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, Khoury J, Jorgensen J, Jain N, Alvarez J, Tippett N, O'Brien S, Jabbour E. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Clinical Oncology, 2019. e-Pub 2019.
Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Sasaki K, Khouri R, Daver N, Pemmaraju N, Khoury J, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien S, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American Society of Clinical Oncology, 2019. e-Pub 2019.
Short NJ, Rafei H, Daver N, Hwang H, Ning J, Cortes J, Jorgensen J, Kadia T, DiNardo C, Wang S, Jabbour E, Popat U, Oran B, Konopleva M, Garcia-Manero G, Borthakur G, Bhalla K, Issa G, Kantarjian H, Ravandi F. Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. American Society of Clinical Oncology, 2019. e-Pub 2019.
Samra B, Richard-Carpentier G, Ravandi F, Kadia TM, Guerra VA, Daver NG, DiNardo CD, Issa GC, Bose P, Yilmaz M, Ohanian M, Borthakur GM, Garcia-Manero G, Pierce SA, Cortes JE, Kantarjian HM, Short NJ. Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019. e-Pub 2019.
Short NJ, Garcia-Maner G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II trial. American Society of Hematology 59th Annual Meeting, 2017. e-Pub 2017.
Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE, Bueso-Ramos CE. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma 58(10):2508-2510, 2017. e-Pub 2017. PMID: 28264600.
Short NJ, Kantarjian H, O’Brien S, Ravandi F, Thomas DA, Garcia-Manero G, Daver N, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson P, Cortes J, Jabbour E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. American Society of Clinical Oncology, 2017. e-Pub 2017.
Short NJ, Jabbour E, Ravandi F, Daver N, Pemmaraju N, Thomas DA, Yilmaz M, Kadia T, Sasaki K, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O’Brien S, Kantarjian H. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. American Society of Clinical Oncology, 2017. e-Pub 2017.
Short NJ, Jabbour E, Ko H, Ravandi F, Thomas D, Garcia-Manero G, Khouri R, Cortes J, Wierda W, Verstovsek S, Estrov Z, Ferrajoli A, Thompson P, Pierce S, Kantarjian H. Outcomes of adult patients with relapsed/refractory Burkitt or Burkitt-like leukemia/lymphoma. American Society of Hematology, 2016. e-Pub 2016.
Short NJ, Ravandi F, Huang X, Cortes J, Pemmaraju N, Daver N, Khouri R, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia T, Wierda W, DiNardo C, O’Brien S, Shah SA, Pike A, Brandt M, Kantarjian H, Jabbour E. Updated results of a randomized phase II trial of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. American Society of Clinical Oncology, 2016. e-Pub 2016.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A phase II trial of omacetaxine mepesuccinate for patients with high-risk myelodysplastic syndrome after failure of hypomethylating agents. American Society of Hematology, 2016. e-Pub 2016.
Short NJ, Kantarjian H, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, Marin D, O’Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Jabbour E. Achievement of minimal residual disease negativity by multiparameter flow cytometry is an important therapeutic endpoint in patients with relapsed/refractory B-cell acute lymphoblastic leukemia receiving salvage treatment. American Society of Hematology, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Thomas D, Daver N, Kadia T, Konopleva M, Jain N, Short NJ, Jeanis V, Moore G, Garris R, Garcia-Manero G, Cortes J, O’Brien S, Jabbour E. Propensity score analysis: frontline therapy with hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. American Society of Clinical Oncology, 2016. e-Pub 2016.
Short NJ, Ravandi F, Cortes JE, Garris R, O’Brien SM, Patel K, Jorgensen JL, Khoury J, Garcia-Manero G, Thomas D, Kantarjian H, Jabbour E. Patterns of relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who achieve complete molecular response with chemotherapy plus a tyrosine kinase inhibitor. American Society of Hematology, 2016. e-Pub 2016.
Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin CC, Khouri MR, Cortes JE, Garris R, O’Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional chromosomal abnormalities in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with tyrosine kinase inhibitors: differential outcomes according to type of chromosomal abnormality. American Society of Hematology, 2016. e-Pub 2016.
Short NJ, Jabbour E, Cortes JE, Garris R, O’Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. American Society of Hematology, 2016. e-Pub 2016.
Short NJ, Benton CB, Nogueras-Gonzalez G, Hokanson J, Gu L, Ravandi F, Garcia-Manero G, Brandt M, Pierce S, Konopleva M, Cortes JE, Kantarjian HK, Quintas-Cardama A, Andreeff M. Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction. American Society of Clinical Oncology, 2015. e-Pub 2015.
Short NJ, Garcia-Manero G, Montalban Bravo G, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. Low-dose hypomethylating agents are effective in patients with low- or intermediate-1-risk myelodysplastic syndrome: a report on behalf of the MDS Clinical Research Consortium. American Society of Hematology, 2015. e-Pub 2015.
Short NJ, Kantarjian HM, Jabbour E, O’Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia T, Daver N, Borthakur G, Cortes JE, Ravandi F. Persistence of cytogenetic abnormalities at complete remission is not prognostic for relapse-free or overall survival in adult patients with acute lymphoblastic leukemia. American Society of Hematology, 2015. e-Pub 2015.
Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O’Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. American Society of Clinical Oncology, 2015. e-Pub 2015.

Book Chapters

Chew, S, Short, NJ, Kantarjian, HM, Jabbour, EJ. Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, 219-233, 2021.
Assi R, Short NJ. Malignant Hematological Diseases: Blast Crisis. In: Oncologic Critical Care, 2018.
Short NJ, Battinelli E. Pharmacologic therapy of anemia. In: Anemia: Pathophysiology, Diagnosis and Management, 2018.

Letters to the Editor

Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
Ravandi F, Zhou S, Short N. The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply. JAMA Oncol 7: 784-785, 2021.
Short NJ, Ravandi F. 10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply. Lancet Haematol 6: e178, 2019.
Short NJ, Kantarjian H, Jabbour E. Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer 123: 4935-6, 2017.

Less

Selected Presentations & Talks

National Presentations

2025. "Should the Initial Therapy for FLT3-Mutant AML be Aza + Ven + FLT3i or Intensive Chemotherapy + FLT3i?". Invited. Acute Leukemia Forum. La Jolla, CA, US.
2024. “Frontline Treatment of ALL in 2024”. Invited. Louisville Hematology Highlights Symposium. Louisville, TN, US.
2024. Open discussion with peers on the flow of ideas, knowledge, and research in AML. Invited. The International Workshop on Acute Leukemia (iwAL). Phoenix, AZ, US.
2024. "Triplet Therapy for Older Patients with AML Unfit for Intensive Chemotherapy". Invited. 24th Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies. Hilton Head, SC, US.
2023. "Chemotherapy-free Treatment of Ph+All". Invited. MD Anderson Scripps Cancer Center. La Jolla, CA, US.
2022. “MRD in AML”. Invited. PACE Program – Practical Approach of MDS and AML Treatment in 2022,. Houston, TX, US.
2022. “Managed Care Considerations in the Treatment and Management of Acute Myeloid Leukemia (AML): Optimizing Decision-Making Strategies for Improved Clinical and Economic Outcomes,”. Invited. 2022 Fall Managed Care Forum. Las Vegas, NV, US.
2022. “Treatment of Relapsed/Refractory ALL”. Invited. NCCN 2022 Annual Congress: Hematological Malignancies. New York, NY, US.
2022. “Treatment of Ph+ ALL in Adults: Moving Toward Chemotherapy-Free Regimens,” 3rd Colloquium of Acute Leukemia and Myelodysplastic Syndrome". Invited. (CLAS). Virtual, US.
2022. “Transplant for Ph+ ALL in First Remission is No Longer Standard of Care.”. Invited. Kuwait Best of ASH 2021. Virtual, US.
2022. “Ph+ ALL: Post-Remission and Maintenance Treatment for Non-Transplanted Patients”. Invited. European School of Haematology (ESH). Virtual, US.
2021. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Conference. American Society of Hematology.
2021. "State-of-the-Art Therapy for Acute Lymphoblastic Leukemia". Invited. Montefiore Einstein Cancer Center.
2021. "Acute Lymphoblastic Leukemia: Cytogenetic and Molecular Alterations and the Rationale for Treatment Selection". Invited. Cvent.
2021. "Next Generation TKIs for Ph+ ALL". Invited. European School of Haematology (ESH).
2020. Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies. Conference. American Society of Hematology, US.
2020. A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy. Conference. American Society of Hematology, US.
2020. Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Conference. American Society of Hematology, US.
2020. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. Conference. American Society of Hematology, US.
2020. "Immune vs. Chemotherapy in ALL". Invited. CLAS - Coloquio de Leucemias Agudas y Sindrome Mielodisplasico.
2019. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Conference. American Society of Hematology. Orlando, FL, US.
2019. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Conference. American Society of Hematology. Orlando, FL, US.
2019. Achievement of Complete Remission (CR) with Measurable Residul Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. Conference. American Society of Hematology. Orlando, FL, US.
2018. "Scouting for New Players: Future Directions in ALL". Invited. American Society of Hematology Annual Meeting Satellite Symposium. San Diego, CA, US.
2018. "MD Anderson Clinical Trials in ALL". Invited. Society for Adolescent and Young Adult Oncology Leukemia Symposium. Newport Beach, CA, US.
2017. "Ph + ALL: What's New?" Excellence in Acute Lymphoblastic Leukemia Treatment Transatlantic (ExALLt). Invited. "Ph + ALL: What's New?" Excellence in Acute Lymphoblastic Leukemia Treatment Transatlantic (ExALLt). Houston, TX, US.

International Presentations

2025. "Frontline Treatment of Ph+ ALL and the Emerging Role of Chemotherapy-Free Regimens. Invited. 3rd SOHO - Israel Meeting and The Davidoff Conference: State of the Art & Next Questions. Tel Aviv, IL.
2025. "Special Education Session: Next Generation Clinical Sequencing and MRD Evaluation". Invited. American Society of Hematology (ASH). Yokohama, JP.
2024. "Chemotherapy- Free Regimens for Philadelphia Chromosome Positive (Ph+) ALL.". Invited. The 86th Annual Meeting of JSH. Kyoto, JP.
2022. “Ponatinib Combination Strategies in Ph+ ALL”. Invited. International Workshop on Acute Leukemias 2022. Nice, FR.
2022. “Optimization of Treatment for Adults with Newly Diagnosed ALL”. Invited. 8th Amgen Medical Excellence Summit (CEMA 2022). Cancun, MX.
2020. "Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia". Invited. International Academic Oncology Virtual Meeting, Instituto Nacional de Cancerologia – Mexico, MX.
2019. "Optimizing the Use of FLT3 Inhibitors in AML". Invited. The European Congress on Leukemias: Between Cutting Edge and Grey Zone Controversies. Vienna, AU.

Formal Peers

2023. "Frontline Treatment of Adult ALL in 2023". Invited. "Frontline Treatment of Adult ALL om 2023". New York, NY, US.

Less

Grant & Contract Support

Date:	2023 - 2026
Title:	Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	PA-20-185

Date:	2023 - 2026
Title:	Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML), Break Through Cancer
Funding Source:	Break Through Cancer
Role:	Co-PI

Date:	2020 - 2022
Title:	Non-Invasive Monitoring of Measurable Residual Disease in Patients with Acute Myeloid Leukemia Using Circulating Cell-Free DNA
Funding Source:	IRG - Internal Research Grant
Role:	PI
ID:	RCTS#58881

Date:	2019 - 2022
Title:	A phase II study of azacitidine, venetoclax and pevonedistat in adults with newly diagnosed secondary or therapy-related AML
Funding Source:	American Society of Hematology (ASH)
Role:	PI

Date:	2019 - 2022
Title:	Paul Calabresi Clinical Oncology Award
Funding Source:	NIH/NCI
Role:	Faculty Scholar
ID:	K12-CA088084-19

Date:	2017 - 2018
Title:	Digital Droplet PCR of Somatic Mutations as a Sensitive Method to Improve Minimal Residual Disease Detection and Risk Stratification in Acute Myeloid Leukemia
Funding Source:	Leukemia SPORE Career Enhancement Award
Role:	PI

Date:	2017 - 2018
Title:	Improving Prediction of Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Using Next-Generation Sequencing
Funding Source:	Conquer Cancer Foundation
Role:	PI

CV information above last modified April 18, 2025

Nicholas James Short, MD

About Dr. Short

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Acute lymphocytic leukemia (ALL)

Acute myeloid leukemia (AML)

Leukemia Department

Cancer Medicine Division

Help #EndCancer

Nicholas James Short, MD

About Dr. Short

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Acute lymphocytic leukemia (ALL)

Acute myeloid leukemia (AML)

Leukemia Department

Cancer Medicine Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer